The management of Type I and Type II DiabetesMellitus has improved because of tremendousimprovement in Insulins over the years, butunfortunately majority of patients in our countrycannot afford these, especially the human insulin, andare deprived of the benefits. Access to insulin shouldbe regular and uninterrupted.Insulin therapy has changed the outlook of Type I -IDDM from certain death to almost normal existence.The discovery of Banting and Best in 1921, was thegreatest breakthrough in this field. Since thencontinuous improvement in Insulins is taking place. InI980\s Recombinant DNA origin insulin came intouse. These insulins are less antigenic, purer, betterabsorbed and lesser doses are required as compared toanimal origin insulins. Human Insulin was firstproduct of biotechnology to enter the clinical Arena2.By 1950 exact structure of insulin molecule wasknown3. In developed countries the prognosis ofDiabetes has dramatically improved over last twentyyears with life expectancy approaching towardsnormal, especially in Denmark4.


Skyler JS Symposium Human Insulin or recombinant

DNA origin Diabetes care 5 (2) 1-186 1983.

Skyler JS Human Insulin after Ten years. Diabetes Care


Bliss M History of insulin Diabetes care vol 16, Pg4-7

Cathelineau. G. Implementation of the declaration of

St. Vincent diabetic Metabol. 20: 337-4, 1994.

DCCT. The diabetes control and complications trial

Research group (DCCT) J. Am. Med. Assoc-276:

- 15,1996.

UKPDS. UK prospective Diabetes study. Intensive

blood glucose control with sulphonylureas or insulin

compared to conventional treatment and risk of

complications with Type 2 Diabetes. Lancet: 352:837-

; 1998.

Mbanya JC Insulin therapy in developing countries.

Implications of chronic shortages. Int: Diab:

Monitor. 12.1; 4-6,2000

Santiago JV Lessons from diabetes control +

complications trial. Diabetes: 42, 1549-54, 1993.

King H. Insulin, availability, affordability, and

harmonization. WHO Drug, 4;219-23, 19